Our findings may have important therapeutic implications because a biased D2 receptor ligand that decreases G protein‐mediated signaling, while sparing arrestin‐mediated signaling, might be an effective treatment in hyperkinetic movement disorders. This evidence concerns the gene SAG and movement disorder.